LDN Treatment for Ovarian Cancer Recent Research
Ovarian cancer is the leading cause of death from gynecological malignancies. Although initial therapeutic modalities are successful, 65% of these women relapse with only palliative treatments available thereafter
The following research article on PubMed concluded Low Dose Natrexone (LDN) to be a beneficial treatment option for ovarian cancer. The following results were stated:
“These preclinical data may offer a non-toxic and efficacious pathway-related treatment that can benefit patients with ovarian cancer.”
CLICK HERE to read more
Please read about the LDN Research Trust!